Pharma major Lupin received the Establishment Inspection Report(EIR) after closure of the US FDA inspection of its Nagpur, India Facility which was conducted on between January 6, 2020 and January 10, 2020.
Nilesh Gupta, Managing Director, Lupin said, “We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites.”
The company has fifteen manufacturing sites, seven research centres and more than 20,000 professionals working globally.